Propanc Biopharma (PPCB) Total Liabilities (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Total Liabilities of $3.7 million for Q4 2025, down 13.64% year-over-year from $4.2 million in Q4 2024, and up 1.24% quarter-over-quarter from $3.6 million in Q3 2025.
Propanc Biopharma (PPCB) Total Liabilities (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Total Liabilities for 15 consecutive years, with $3.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities fell 13.64% year-over-year to $3.7 million; the TTM figure through Dec 2025 stood at $3.7 million (down 13.64% YoY), while the FY2025 annual figure was $5.7 million, up 48.66% from the prior year.
- Total Liabilities rose to $3.7 million in Q4 2025 per PPCB's latest filing, from $3.6 million in the prior quarter.
- Across five years, Total Liabilities topped out at $5.7 million in Q2 2025 and bottomed at $2.4 million in Q3 2021.
- Historically, Total Liabilities has averaged $3.5 million across 5 years, with a median of $3.2 million in 2023.
- Annual changes were most pronounced in 2021 — Total Liabilities slumped 38.26% — and 2025, when it surged 48.66%.
- Propanc Biopharma's Total Liabilities stood at $3.0 million in 2021, then declined by 0.56% to $3.0 million in 2022, then increased by 25.87% to $3.8 million in 2023, then advanced by 11.35% to $4.2 million in 2024, then declined by 13.64% to $3.7 million in 2025.
- Business Quant data shows PPCB's Total Liabilities at $3.7 million in Q4 2025, $3.6 million in Q3 2025, and $5.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 3.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.66 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Jun 30, 2025 | 5.73 Mn |
| Mar 31, 2025 | 4.44 Mn |
| Dec 31, 2024 | 4.24 Mn |
| Sep 30, 2024 | 4.17 Mn |
| Jun 30, 2024 | 3.85 Mn |
| Mar 31, 2024 | 3.74 Mn |
| Dec 31, 2023 | 3.81 Mn |
| Sep 30, 2023 | 3.17 Mn |
| Jun 30, 2023 | 3.18 Mn |
| Mar 31, 2023 | 3.09 Mn |
| Dec 31, 2022 | 3.02 Mn |
| Sep 30, 2022 | 2.86 Mn |
| Jun 30, 2022 | 3.11 Mn |
| Mar 31, 2022 | 3.12 Mn |
| Dec 31, 2021 | 3.04 Mn |
| Sep 30, 2021 | 2.37 Mn |
| Jun 30, 2021 | 3.08 Mn |
| Mar 31, 2021 | 3.03 Mn |